Heparin-induced thrombocytopenia immune complexes activate the inflammasome pathway in a complement-dependent manner

Area of Science:

• Immunology
• Hematology
• Pharmacology

Background:

• Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction triggered by IgG antibodies against platelet factor 4 (PF4)/heparin complexes.
• These immune complexes (ICs) activate FcγRIIA receptors, promoting prothrombotic signaling and cytokine release.

Purpose of the Study:

• To investigate the role of inflammasome activation and IL-1β release in HIT.
• To elucidate the mechanisms underlying HIT pathogenesis involving FcγRIIA, complement, and inflammasome pathways.

Main Methods:

• Assessed IL-1β secretion in whole blood and PBMCs challenged with HIT ICs or patient plasma.
• Utilized FcγRIIA, complement, and NLRP3 inflammasome inhibitors to determine pathway requirements.
• Employed FcγRIIA transgenic mice lacking Nlrp3 in a thrombosis model.

Main Results:

• HIT ICs significantly increased IL-1β secretion in a FcγRIIA-dependent manner.
• IL-1β release required complement activation and was reduced by the NLRP3 inhibitor MCC950.
• Nlrp3 was essential for severe thrombocytopenia and thrombosis in a mouse model.

Conclusions:

• HIT ICs activate the inflammasome pathway via FcγRIIA and complement.
• IL-1β secretion is a critical mediator of HIT pathology.
• Targeting the inflammasome pathway may offer therapeutic strategies for HIT.